Chapter/Section Purchase

1 Introduction to Research & Analysis Reports
1.1 Targeted Drug BRAF Inhibitors for NSCLC Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Targeted Drug BRAF Inhibitors for NSCLC Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Targeted Drug BRAF Inhibitors for NSCLC Overall Market Size
2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size: 2021 VS 2028
2.2 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Targeted Drug BRAF Inhibitors for NSCLC Players in Global Market
3.2 Top Global Targeted Drug BRAF Inhibitors for NSCLC Companies Ranked by Revenue
3.3 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue by Companies
3.4 Top 3 and Top 5 Targeted Drug BRAF Inhibitors for NSCLC Companies in Global Market, by Revenue in 2021
3.5 Global Companies Targeted Drug BRAF Inhibitors for NSCLC Product Type
3.6 Tier 1, Tier 2 and Tier 3 Targeted Drug BRAF Inhibitors for NSCLC Players in Global Market
3.6.1 List of Global Tier 1 Targeted Drug BRAF Inhibitors for NSCLC Companies
3.6.2 List of Global Tier 2 and Tier 3 Targeted Drug BRAF Inhibitors for NSCLC Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Targeted Drug BRAF Inhibitors for NSCLC Market Size Markets, 2021 & 2028
4.1.2 Dabrafenib
4.1.3 Trametinib
4.1.4 Lifirafenib
4.1.5 Other
4.2 By Type - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue & Forecasts
4.2.1 By Type - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2017-2022
4.2.2 By Type - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2023-2028
4.2.3 By Type - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2021 & 2028
5.1.2 Squamous Cell Carcinoma of NSCLC
5.1.3 Adenocarcinoma of NSCLC
5.1.4 Large Cell Carcinoma of NSCLC
5.2 By Application - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue & Forecasts
5.2.1 By Application - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2017-2022
5.2.2 By Application - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2023-2028
5.2.3 By Application - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2021 & 2028
6.2 By Region - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue & Forecasts
6.2.1 By Region - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2017-2022
6.2.2 By Region - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2023-2028
6.2.3 By Region - Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2017-2028
6.3.2 US Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.3.3 Canada Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.3.4 Mexico Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2017-2028
6.4.2 Germany Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.4.3 France Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.4.4 U.K. Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.4.5 Italy Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.4.6 Russia Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.4.7 Nordic Countries Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.4.8 Benelux Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2017-2028
6.5.2 China Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.5.3 Japan Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.5.4 South Korea Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.5.5 Southeast Asia Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.5.6 India Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2017-2028
6.6.2 Brazil Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.6.3 Argentina Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue, 2017-2028
6.7.2 Turkey Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.7.3 Israel Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.7.4 Saudi Arabia Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
6.7.5 UAE Targeted Drug BRAF Inhibitors for NSCLC Market Size, 2017-2028
7 Players Profiles
7.1 BeiGene
7.1.1 BeiGene Corporate Summary
7.1.2 BeiGene Business Overview
7.1.3 BeiGene Targeted Drug BRAF Inhibitors for NSCLC Major Product Offerings
7.1.4 BeiGene Targeted Drug BRAF Inhibitors for NSCLC Revenue in Global Market (2017-2022)
7.1.5 BeiGene Key News
7.2 Novartis
7.2.1 Novartis Corporate Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Targeted Drug BRAF Inhibitors for NSCLC Major Product Offerings
7.2.4 Novartis Targeted Drug BRAF Inhibitors for NSCLC Revenue in Global Market (2017-2022)
7.2.5 Novartis Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer